Mandatory Gardasil Truth from Fiction Thread #2: "Merck Says It's NOT a Cancer Drug."

The next bit of misinformation on this board regarding Gardasil is that it's a cervical cancer drug. But is this really true?

On its official Gardasil website, Merck explains:



Edited to add:

And from the National Institutes of Health:



To me that slaps Merck, and Rick Perry's executive order mandating Gardasil, right in the ASS!

Edited to concede the fact that NIH cites HPV as "the major cause of cervical cancer," although some cases do exist where HPV is not a factor.

What we are being told - or at the least what has been confused - is that by making Gardasil mandatory (in the case of Texas), it will save lives by obliterating cervical cancer itself. That is a misperception.

So as you can see, Gardasil is NOT a "cancer vaccine." It is a vaccine against certian types of HPV which, according to the NIH quote above, may or may not eventually cause cancer.

The question is, what percentage of the population contracts cervical cancer as a result of HPV

HPV Types 16 and 18 cause 70% of cervical cancer cases

So, what you're saying is that because it only deals with the cause of 70% of cervical cancer cases (and not 100%), we should just ignore it? Tell that to the 70%.

And what about the cases of cervical cancer NOT caused by HPV? That's what I'm getting at, and your response proves my point.

We are hearing nothing about what percentage of the population contracts cervical cancer with no HPV present, thus falsely leading us all to believe that all cervical cancers are caused by HPV.

It could well be that more cervical cancers are diagnosed with no HPV present. If that's the case, then making Gardasil mandatory would seem a wasted effort, clearly designed to fatten Merck's bottom line.

Do the math. It's all right there in your post.

HPV Types 16 and 18 cause 70% of cervical cancer cases

Gee, that would seem to mean that *at most* 30% of cervical cancer is caused by factors other than HPV 16 & 18, right?

100 - 70 = 30.

See? That wasn't so hard.

We are hearing nothing about what percentage of the population contracts cervical cancer with no HPV present

"We" see the answer clearly stated in your posting. "You" somehow have completely missed the utterly obvious.

Again, 100% - 70% = 30%. So, quite obviously, no more than 30% of cervical cancer is caused by non-HPV 16/18 factors.

Edit: clarification

...that Merck makes no such claim about Gardasil preventing ALL forms of cervical cancer. It also makes it clear that the vaccine will not replace annual exams or Pap smears. If people willfully ignore those caveats, then that is on them. Not Merck.

Some protection against any kind of cancer is better than none. If this were about lung cancer, colon cancer, or any other cancer that strikes the population as a whole, any vaccine that provided any percentage of protection would be hailed as a significant medical breakthrough and people would be out the door at their doctors' offices getting it.

Moreover, given that HPV is a sexually transmitted disease, any kind of protection against that is worth it as well. You could remain a virgin until your wedding night but that is no guarantee that the person you sleep with has. Real-life example with another vaccine: In my private life I am at extremely low risk (almost nil) of contracting Hepatitis B. However, in my job I come in contact at times with many people who may have it, namely, with their body fluids. So I have gotten the Hep B series of shots, and am now protected. To be sure, that does not protect me against other diseases I may contract, but at least I know I am protected against *one* of them. So it is with Gardasil and some types of HPV.

I will concede one point. Making Gardasil mandatory for school attendance is a bit of an overkill, and I believe the decision to have their kids vaccinated with it should remain with the parents. But it is also overkill, I think, to discount Gardasil out of hand as some here and elsewhere are hellbent on doing.

If it immunizes against a virus with a strong direct link to the cervical cancer, it may not be a "cancer vaccine" but it will still serve to prevent occurences of the cancer.

As for the "MAY be the cause" well.. um the science is a little bit stronger than that. As I said, distinction without a difference.

An HPV vaccine such as Gardasil will serve to prevent SOME occurences of cervical cancer. This vaccine does not eradicate ALL types of HPV, as the OP outlines. That's why they encourage women to continue to get regular checkups.

And what about cases where cervical cancer is detected with no HPV present?

Or very few. See the item posted by hlthe2b below.

You seem to think that unless a given medical remedy is a 100% cure in all cases that it's a fraud upon the public. The reason Merck can't go claiming it's a 'cancer vaccine' is because even though it's a vaccine against cancer, it is not, medically speaking, technically speaking, a 'cancer vaccine'... and my stance is, and your point is what? As for your point here about, well look, it doesn't eradicate all types of HPV, and your point is what?... That a vaccine that is truthfully claimed to attack a virus, should instead attack the cancer itself, or else it's not a vaccine at all? There is no cancer vaccine because cancer is not a virus. There is no virus called cancer. So what.

melanoma. But it's not technically a vaccine, because there's no virus involved. It stimulates immunity against the actual cancer cells. But I'm sure the OP knows nothing of this, and couldn't comprehend those big words anyway.

In 1999, my mother died of malignant melanoma. Ironically she worked for the National Cancer Institute at NIH in Bethesda. She accepted a trial of the melanoma vaccine and at that time, unfortunately, it only served to make her cancer worse. Hopefully they've improved it by now.

No hard feelings...but sometimes ya just never know.

Because it doesn't prevent ALL cervical cancer it should be not used? Of course people should still get checkups.

Recent studies have shown that HPV-DNA can be found in 99.7% of all
cervical carcinomas, with HPV types 16, 18, 45 and 31 being the most
frequent.2,4–7 It has now been proven beyond reasonable doubt that infection
with an HR-HPV is a necessary prerequisite for the development of
cervical cancer, and the World Health Organization (WHO) has declared
HPV16 and HPV18 as carcinogenic agents for humans.

the full pdf text of this article is publically available:
http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp22.pdf


*********************************************************************************

Additional References: (available through most university and medical school libraries)
REFERENCES
1. Roden RB, Lowy DR, Schiller JT. Papillomavirus is resistant to desiccation.
Journal of Infectious Diseases, 1997, 176: 1076–1079.
2. Bosch FX, Lorincz A, Muñoz N et al. The causal relation between human
papillomavirus and cervical cancer. Journal of Clinical Pathology, 2002, 55:
244–265.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical
application. Nature Review of Cancer, 2002, 342–350.
4. Bosch FX, Manos MM, Muñoz N et al. Prevalence of human papillomavirus
in cervical cancer: a worldwide perspective. Journal of the National Cancer
Institute, 1995, 87: 796–802.
5. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in
invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer,
2003, 88: 63–73.
6. Muñoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human
papillomavirus types associated with cervical cancer. New England Journal of
Medicine, 2003, 348: 518–527.
7. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. Journal of Pathology,
1999, 189: 12–19.
8. Chan PJ, Seraj IM, Kalugdan TH, King A. Blastocysts exhibit preferential
uptake of DNA fragments from the E6-E7 conserved region of the human
papillomavirus. Gynecologic Oncology, 1995, 58: 194–197.
9. de Villiers EM. Importance of human papillomavirus DNA typing in the
diagnosis of anogenital warts in children. Archives of Dermatology, 1995, 131:
366–367.
10. de Villiers EM, Fauquet C, Broker TR et al. Classification of papillomaviruses.
Virology, 2004, 324: 17–27.
11. Myers G, Halpern A, Baker C et al. Human Papillomavirus Compendium: A
Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los
Alamos, New Mexico, Los Alamos National Laboratory, 1996.
12. Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human
papillomaviruses: correlation with clinical manifestations. Journal of General
Virology, 1992, 73: 2653–2660.
13. Pfister H, Fuchs PG. Anatomy, taxonomy and evolution of papillomaviruses.
Intervirology, 1994, 37:143–149.
14. Iftner T. Papillomavirus genomes: sequence analysis related to functional
aspects. In: Pfister H (ed.) Papillomaviruses and Human Cancer. Boca Raton,
Florida, CRC Press, 1990: 181–203.
15. Androphy EJ, Hubbert NL, Schiller JT, Lowy DR. Identification of the hPV-16
E6 protein from transformed mouse cells and human cervical carcinoma cell
lines. EMBO Journal, 1987, 6: 989–992.
16. Sedman, SA, Barbosa, MS, Vass, WC et al. The full-length E6 protein of
human papillomavirus type 16 has transforming and trans-activating activities
and cooperates with E7 to immortalize keratinocytes in culture. Journal of
Virology, 1991, 65: 4860–4866.
17. Von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L. Correlation
of modified human papilloma virus early gene expression with altered growth
properties in C4–1 cervical carcinoma cells. Cancer Research, 1988, 48:
3780–3786.
18. zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to
preventing a major human cancer (Editorial). Journal of the National Cancer
Institute, 2001, 93: 252–253.
19. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in
HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor
suppressor pathways. Proceedings of the National Academy of Science of the
USA, 2000, 97: 12513–12518.
20. Munger K, Howley PM. Human papillomavirus immortalization and
transformation functions. Virus Research, 2002, 89: 213–228.
21. Mantovani F, Banks L. The human papillomavirus E6 protein and its
contribution to malignant progression. Oncogene, 2001, 20: 7874–7887.
22. Scheffner M, Werness BA, Huibregtse JM et al. The E6 oncoprotein encoded
by human papillomavirus types 16 and 18 promotes the degradation of p53.
Cell, 1990, 63: 1129–1136.
23. Huibregste JM, Scheffner M, Howley PM. A cellular protein mediates
association of p53 with the oncoprotein of human papillomavirus types 16 or
18. EMBO Journal, 1991,10: 4129–4135.
24. Hengstermann A, Linares LK, Ciechanover A et al. Complete switch from
Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical
cancer cells. Proceedings of the National Academy of Science of the USA, 2001,
98: 1218–1223.
25. Iftner T, Elbel M, Schopp B et al. Interference of papillomavirus E6 protein
with single-strand break repair by interaction with XRCC1. EMBO Journal,
2002, 21: 4741–4748.
26. Dyson N. The regulation of E2F by pRB-family proteins. Genes and
Development, 1998, 12: 2245–2262.
27. Munger K, Basile JR, Duensing S et al. Biological activities and molecular
targets of the human papillomavirus E7 oncoprotein. Oncogene, 2001, 20:
7888–7898.
28. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces
degradation of retinoblastoma protein through the ubiquitin-proteasome
pathway. Cancer Research, 1996, 56: 4620–4624.
29. Chellappan S, Kraus VB, Kroger B et al. Adenovirus E1A, simian virus 40
tumor antigen, and human papillomavirus E7 protein share the capacity to
disrupt the interaction between transcription factor E2F and the retinoblastoma
gene product. Proceedings of the National Academy of Science of the USA,
1992, 89: 4549–4553.
30. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human
papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in
retinoblastoma protein binding and other properties. Journal of Virology, 1990,
64: 723–730.
31. Egawa K. Do human papillomaviruses target epidermal stem cells?
Dermatology, 2003, 207: 251–254.
32. Schmitt A, Rochat A, Zeltner R et al. The primary target cells of the high-risk
cottontail rabbit papillomavirus colocalize with hair follicle stem cells. Journal
of Virology, 1996, 70: 1912–1922.
33. Stanley MA. Virus–keratinocyte interactions in the infectious cycle. In: Stern
PL, Stanley MA (eds) Human Papillomaviruses and Cervical Cancer – Biology
and Immunology. Oxford, Oxford Medical Publications, 1994: 116–131.
34. Laimins LA. Human papillomaviruses target differentiating epithelium for
virion production and malignant conversion. Seminars in Virology, 1996, 7:
305–313.
35. Cheng S, Schmidt-Grimminger DC, Murant T et al. Differentiation-dependent
up-regulation of the human papillomavirus E7 gene reactivates cellular DNA
replication in suprabasal differentiated keratinocytes. Genes and Development,
1995, 9: 2335–2349.
36. Halbert CL, Demers GW, Galloway DA. The E6 and E7 genes of human
papillomavirus type 6 have weak immortalizing activity in human epithelial
cells. Journal of Virology, 1992, 66: 2125–2134.
37. Ruesch MN, Laimins LA. Human papillomavirus oncoproteins alter
differentiation-dependent cell cycle exit on suspension in semisolid medium.
Virology, 1998, 250: 19–29.
38. Cullen AP, Reid R, Campion M, Lörincz AT. Analysis of the physical state of
different human papillomavirus DNAs in intraepithelial and invasive cervical
neoplasm. Journal of Virology 1991, 65(2): 606–612.
39. Del Vecchio AM, Romanczuk H, Howley PM, Baker CC. Transient replication
of human papillomavirus DNAs. Journal of Virology 1992, 66: 5949–5958.
40. Frattini MG, Lim HB, Laimins LA. In vitro synthesis of oncogenic human
papillomaviruses requires episomal genomes for differentiation-dependent late
expression. Proceedings of the National Academy of Science of the USA, 1996,
93: 3062–3067.
41. Peyton CL, Schiffman M, Lörincz AT et al. Comparison of PCR- and hybrid
capture-based human papillomavirus detection systems using multiple cervical
specimen collection strategies. Journal of Clinical Microbiology, 1998, 36:
3248–3254.
42. Peyton CL, Gravitt PE, Hunt WC et al. Determinants of genital human
papillomavirus detection in a US population. Journal of Infectious Diseases,
2001, 183: 1554–1564.
43. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus
detection and typing by cycle sequencing, line blotting, and hybrid capture.
Journal of Clinical Microbiology, 2000, 38: 651–655.
44. Castle PE, Schiffman M, Burk RD et al. Restricted cross-reactivity of
hybrid capture 2 with nononcogenic human papillomavirus types. Cancer
Epidemiology Biomark Preview, 2002, 11: 1394–1399.
45. Lörincz AT, Anthony J. Advances in HPV detection by hybrid capture.
Papillomavirus Reports, 2001, 145–154.
46. Bernard HU, Chan SY, Manos MM et al. Identification and assessment of
known and novel human papillomaviruses by polymerase chain reaction
amplification, restriction fragment length polymorphisms, nucleotide sequence,
and phylogenetic algorithms. Journal of Infectious Diseases, 1994, 170:
1077–1085.
47. de Roda Husman AM, Walboomers JMM, Van den Brule AJC et al. The use of
general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly
conserved sequences improves human papillomavirus detection by polymerase
chain reaction. Journal of General Virology, 1995, 76: 1057–1062.
48. van den Brule AJ, Meijer CJ, Bakels V et al. Rapid detection of human
papillomavirus in cervical scrapes by combined general primer-mediated and
type-specific polymerase chain reaction. Journal of Clinical Microbiology,
1990, 28: 2739–2743.
49. Jacobs MV, Snijders PJF, Van den Brule AJC et al. A general primer GP5+/
GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14
high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings.
Journal of Clinical Microbiology, 1997, 35: 791–795.
50. Manos MM, Ting Y, Wright DK et al. Use of polymerase chain reaction
amplification for detection of genital papillomavirus. Cancer Cells, 1989, 29:
20–27.
51. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human
papillomavirus types by using L1 consensus PCR products by a singlehybridization,
reverseline blot detection method. Journal of Clinical
Microbiology, 1998, 36: 3020–3027.
52. Gravitt PE, Peyton CL, Alessi TQ et al. Improved amplification of genital
human papillomaviruses. Journal of Clinical Microbiology, 2000, 38: 357–361.
53. Jacobs MV, de Roda Husman AM, Van den Brule AJC et al. Group-specific
differentiation beween high- and low-risk human papillomavirus genotypes
by general primer-mediated PCR and two cocktails of oligonucleotide probes.
Journal of Clinical Microbiology, 1995, 33: 901–905.
54. Kleter B, Van Doorn LJ, ter Schegget J et al. Novel short-fragment PCR
assay for highly sensitive broad-spectrum detection of anogenital human
papillomaviruses. American Journal of Pathology, 1998, 153: 1731–1739.
55. Kleter B, Van Doorn LJ, Schrauwen L et al. Development and clinical
evaluation of a highly sensitive PCR-reverse hybridization line probe assay for
detection and identification of anogenital human papillomavirus. Journal of
Clinical Microbiology, 1999, 37: 2508–2517.
56. Iftner T, Villa LL. Human papillomavirus technologies. Journal of the National
Cancer Institute Monographs, 2003, 31: 80–88.
57. Castle PE, Lorincz AT, Scott DR et al. Comparison between prototype hybrid
capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection
of high-grade cervical intraepithelial neoplasia and cancer. Journal of Clinical
Microbiology, 2003, 41: 4022–4030.
58. Qu W, Jiang G, Cruz Y et al. PCR detection of human papillomavirus:
comparison between MY09/MY11 and GP5+/GP6+ primer systems. Journal of
Clinical Microbiology, 1997, 35: 1304–1310.
59. Swan DC, Tucker RA, Tortolero-Luna G et al. Human papillomavirus (HPV)
DNA copy number is dependent on grade of cervical disease and HPV type.
Journal of Clinical Microbiology, 1999, 37, 1030–1034.
60. Van Doorn LJ, Quint W, Kleter B et al. Genotyping of human papillomavirus
in liquid cytology cervical specimens by the PGMY line blot assay and the
SPF(10) line probe assay. Journal of Clinical Microbiology, 2002, 40: 979–983.
61. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific
DNA and RNA persistence: implications for cervical disease progression and
monitoring. Journal of Medical Virology, 2004, 73: 65–70.
62. Sotlar K, Selinka HC, Menton M et al. Detection of human papillomavirus type
16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes
by nested RT-PCR. Gynecologic Oncology, 1998, 69: 114–121.
63. Melsheimer P, Kaul S, Dobeck S, Bastert G. Immunocytochemical detection
of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with
detection of HPV L1 DNA. Acta Cytologica, 2003, 47: 124–128.
64. Keating JT, Cviko A, Riethdorf S et al. Ki-67, cyclin E, and p16INK4 are
complimentary surrogate biomarkers for human papilloma virus-related
cervical neoplasia. American Journal of Surgical Pathology, 2001, 25: 884–
891.
65. Freeman A, Morris LS, Mills AD et al. Minichromosome maintenance proteins
as biological markers of dysplasia and malignancy. Clinical Cancer Research,
1999, 5: 2121–2132.
66. Williams GH, Romanowski P, Morris L et al. Improved cervical smear
assessment using antibodies against proteins that regulate DNA replication.
Proceedings of the National Academy of Science of the USA, 1998, 95: 14932–
14937.
67. Klaes R, Friedrich T, Spitkovsky D et al. Overexpression of p16(INK4A) as a
specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.
International Journal of Cancer, 2001, 92: 276–284.
68. Murphy N, Ring M, Killalea AG et al. p16INK4A as a marker for cervical
dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. Journal
of Clinical Pathology, 2003, 56: 56–63.
69. Riethdorf L, Riethdorf S, Lee KR et al. Human papillomaviruses, expression of
p16, and early endocervical glandular neoplasia. Human Pathology, 2002, 33:
899–904.
70. Serrano M. The tumor suppressor protein p16INK4a. Experimental Cell
Research, 1997, 237: 7–13.
71. Xiong Y, Hannon GJ, Zhang H et al. p21 is a universal inhibitor of cyclin
kinases. Nature, 1993, 366: 701–704.
72. Bibbo M, DeCecco J, Kovatich AJ. P16INK4A as an adjunct test in liquidbased
cytology. Analytical and Quantitative Cytology and Histology, 2003, 25:
8–11.
73. Saqi A, Pasha TL, McGrath CM et al. Overexpression of p16INK4A in liquidbased
specimens (SurePath) as marker of cervical dysplasia and neoplasia.
Diagnostic Cytopathology, 2002, 27: 365–370.
74. Negri G, Egarter-Vigl E, Kasal A et al. p16INK4a is a useful marker for
the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an
immunohistochemical study with immunocytochemical correlations. American
Journal of Surgical Pathology, 2003, 27: 187–193.
75. Steenbergen RD, OudeEngberink VE, Kramer D et al. Down-regulation of
GATA-3 expression during human papillomavirus-mediated immortalization
and cervical carcinogenesis. American Journal of Pathology, 2002, 160:
1945–1951.
76. Wollscheid V, Kuhne-Heid R, Stein I et al. Identification of a new proliferationassociated
protein NET-1/C4.8 characteristic for a subset of high-grade cervical
intraepithelial neoplasia and cervical carcinomas. International Journal of
Cancer, 2002, 99: 771–775.
77. Christensen ND, Dillner J, Eklund C et al. Surface conformational and linear
epitopes on HPV-16 and HPV-18 virus-like particles as defined by monoclonal
antibodies. Virology, 1996, 223: 174–184.
78. Cowsert LM, Lake P, Jenson AB. Topographical and conformational epitopes
pf bovine papillomavirus type 1 defined by monoclonal antibodies. Journal of
the National Cancer Institute, 1987, 79: 1053–1057.
79. Christensen ND, Kirnbauer R, Schiller JT et al. Human papilloma virus types
6 and 11 have antigenically distinct strongly immunogenic conformationally
dependent neutralizing etiopes. Virology, 1994, 205: 329–335.
80. Andersson-Ellstrom A, Dillner J, Hagmar B et al. No serological evidence for
non-sexual spread of HPV16. Lancet, 1994, 344: 1435.
81. Andersson-Ellstrom A, Dillner J, Hagmar B et al. Comparison of development
of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV
DNA among sexually experienced and virginal young girls. A longitudinal
cohort study. Sexually Transmitted Diseases, 1996, 23: 234–238.
82. Carter JJ, Koutsky LA, Wipf GC et al. The natural history of human
papillomavirus type 16 capsid antibodies among a cohort of university women.
Journal of Infectious Diseases, 1996, 174: 927–936.
83. Wikstrom A, Van Doornum GJ, Quint WG et al. Identification of human
papillomavirus seroconversions. Journal of General Virology, 1995, 76 ( Pt 3):
529–539.
84. Wikstrom A, Van Doornum GJ, Kirnbauer R et al. Prospective study on the
development of antibodies against human papillomavirus type 6 among patients
with condyloma acuminata or new asymptomatic infection. Journal of Medical
Virology, 1995, 46: 368–374.
85. Dillner J, Kallings I, Brihmer C et al. Seropositivities to human papillomavirus
types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual
behavior. Journal of Infectious Diseases, 1996, 173: 1394–1398.
86. Kjellberg L, Wang Z, Wiklund F et al. Sexual behaviour and papillomavirus
exposure in cervical intraepithelial neoplasia: a population-based case–control
study. Journal of General Virology, 1999, 80 (Pt 2): 391–398.
87. Viscidi RP, Kotloff KL, Clayman B et al. Prevalence of antibodies to human
papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV
infection among college women. Clinical Diagnostic Laboratory Immunology,
1997, 4: 122–126.
88. Wideroff L, Schiffman MH, Hoover R et al. Epidemiologic determinants of
seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in
cervical HPV-16 DNA-positive and -negative women. Journal of Infectious
Diseases, 1996, 174: 937–943.
89. af Geijersstam V, Eklund C, Wang Z et al. A survey of seroprevalence of human
papillomavirus types 16, 18 and 33 among children. International Journal of
Cancer, 1999, 80: 489–493.
90. Mund K, Han C, Daum R et al. Detection of human papillomavirus type 16
DNA and of antibodies to human papillomavirus type 16 proteins in children.
Intervirology, 1997, 40: 232–237.
91. Wang ZH, Kjellberg L, Abdalla H et al. Type specificity and significance
of different isotypes of serum antibodies to human papillomavirus capsids.
Journal of Infectious Diseases, 2000, 181: 456–462.
92. Shah KV, Viscidi RP, Alberg AJ et al. Antibodies to human papillomavirus 16
and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiology
Biomarkers Preview, 1997, 6: 233–237.
93. Cromme FV, Meijer CJLM, Snijders PJF et al. Analysis of MHC class I and II
expression in relation to presence of HPV genotypes in premalignant cervical
lesions. British Journal of Cancer, 1993, 67: 1372–1380.
94. Glew SS, Connor ME, Snijders PJF et al. HLA expression in pre-invasive
cervical neoplasia in relation to human papilloma virus infection. European
Journal of Cancer, 1993, 29A(14): 1963–1970.
95. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas.
International Journal of Cancer, 1990, 46: 1029–1034.
96. Hilders CG, Houbiers JG, Ravenswaay Claasen HH et al. Association between
HLA-expression and infiltration of immune cells in cervical carcinoma.
Laboratory Investigation, 1993, 69: 651–659.
97. Keating PJ, Cromme FV, Duggan-Keen M et al. Frequency of down-regulation
of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1
expression. British Journal of Cancer, 1995, 72: 405–411.
98. van Driel WJ, Tjiong MY, Hilders CG et al. Association of allele-specific HLA
expression and histopathologic progression of cervical carcinoma. Gynecologic
Oncology, 1996, 62: 33–41.
99. Stellato G, Nieminen P, Aho M et al. Type 1 cytokine response and treatment
outcome of genital HPV lesions. Genitourinary Medicine, 1997, 73: 387–390.
100. Clerici M, Merola M, Ferrario E et al. Cytokine production patterns in cervical
intraepithelial neoplasia: association with human papillomavirus infection.
Journal of the National Cancer Institute, 1997, 89(3): 245–250.
101. Bauer HM, Hildesheim A, Schiffman MH et al. Determinants of genital human
papillomavirus infection in low-risk women in Portland, Oregon. Sexually
Transmitted Diseases, 1993, 20: 274–278.
102. Franco EL, Villa LL, Ruiz A, Costa MC. Transmission of cervical human
papillomavirus infection by sexual activity: differences between low and high
oncogenic risk types. Journal of Infectious Diseases, 1995, 172: 756–763.
103. Hildesheim A, Gravitt P, Schiffman MH et al. Determinants of genital human
papillomavirus infection in low-income women in Washington DC. Sexually
Transmitted Diseases, 1993, 20: 279–284.
104. Kjaer SK, Van den Brule AJC, Bock JE et al. Determinants for genital human
papillomavirus (HPV) infection in 1000 randomly chosen young danish women
with normal Pap smear: are there different risk profiles for oncogenic and
nononcogenic HPV types? Cancer Epidemiology Biomark Preview, 1997, 6:
799–805.
105. Kjaer SK, Chackerian B, van der Brule AJC et al. High-risk human
papillomavirus is sexually transmitted: evidence from a follow-up study of
virgins starting sexual activity (intercourse). Cancer Epidemiology Biomark
Preview, 2001, 10: 101–106.
106. Muñoz N, Kato I, Bosch FX et al. Risk factors for HPV DNA detection in
middle-aged women. Sexually Transmitted Diseases, 1996, 23: 504–510.
107. Rousseau M, Franco E, Villa LL et al. A cumulative case–control study of risk
factor profiles for oncogenic and nononcogenic cervical human papillomavirus
infections. Cancer Epidemiology Biomark Preview, 2000, 9: 469–476.
108. Silins I, Kallings I, Dillner J. Correlates of the spread of human papillomavirus
infection. Cancer Epidemiology, 2000, 9: 953–959.
109. Wheeler CM, Parmenter CA, Hunt WC et al. Determinants of genital human
papillomavirus infection among cytologically normal women attending
the University of New Mexico student health center. Sexually Transmitted
Diseases, 1993, 20: 286–289.
110. Barrasso R, de Brux J, Croissant O, Orth G. High prevalence of papillomavirusassociated
penile intraepithelial neoplasia in sexual partners of women with
cervical intraepithelial neoplasia. New England Journal of Medicine, 1987,
317: 916–923.
111. Bergman A, Nalick R. Prevalence of human papillomavirus infection in men:
comparison of the partners of infected and uninfected women. Journal of
Reproductive Medicine, 1992, 37: 710–712.
112. Bosch FX, Castellsagué X, Muñoz N et al. Male sexual behavior and human
papillomavirus DNA: key risk factors for cervical cancer in Spain. Journal of
the National Cancer Institute, 1996, 88(15): 1060–1067.
113. Castellsagué X, Ghaffari A, Daniel RW et al. Prevalence of penile human
papillomavirus DNA in husbands of women with and without cervical
neoplasia: a study in Spain and Colombia. Journal of Infectious Diseases, 1997,
176: 353–361.
114. Kjaer SK. Case–control study of risk factors for cervical neoplasia in Denmark.
I. Role of the ‘male factor’ on women with one lifetime sexual partner.
International Journal of Cancer, 1991, 48: 39–41.
115. Bosch FX, Muñoz N, de Sanjosé S et al. Importance of human papillomavirus
endemicity in the incidence of cervical cancer: an extension of the hypothesis
on sexual behavior. Cancer Epidemiology Biomark Preview, 1994, 3: 375–379.
116. de Sanjosé S, Palacio V, Tafur L et al. Prostitution, HIV, and cervical neoplasia:
a survey in Spain and Colombia. Cancer Epidemiology Biomark Preview, 1993,
2: 531–535.
117. Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ et al. Human papillomavirus:
a highly prevalent sexually transmitted disease agent among female sex
workers from Mexico City. Sexually Transmitted Diseases, 2001, 28: 125–130.
118. Thomas DB, Ray RM, Kuypers J et al. Human papillomaviruses and cervical
cancer in Bangkok. III. Role of husbands and commercial sex workers.
American Journal of Epidemiology, 2001, 153(8): 740–748.
119. Castellsague X, Bosch FX, Munoz N et al. Male circumcision, penile human
papillomavirus infection, and cervical cancer in female partners. New England
Journal of Medicine, 2002, 346: 1105–1112.
120. Rigoni-Stern. Fatti statistici relativi alle malattie cancerose. Giorn. Prog. Patol.
Terap., 1842, 2: 507–517.
121. Beral V. Cancer of the cervix: a sexually transmitted infection? Lancet, 1974, i:
1037–1040.
122. Skegg DCG, Corwin PA, Paul C, Doll R. Importance of the male factor in
cancer of the cervix. Lancet, 1982, 2: 581–583.
123. Cason J. Perinatal acquisition of cervical cancer-associated papillomaviruses.
British Journal of Obstetrics and Gynaecology, 1996, 103: 853–858.
124. Andersson-Ellstrom A, Hagmar BM, Johansson B et al. Human papillomavirus
deoxyribonucleic acid in cervix only detected in girls after coitus. International
Journal of STD and AIDS, 1996, 7: 333–336.
125. Fairley CK, Chen S, Tabrizi SN et al. Absence of genital human papillomavirus
DNA in virginal women. International Journal of STD and AIDS, 1992, 3:
414–417.
126. Rylander E, Ruusuvaara L, Almstromer MW et al. The absence of vaginal
human papillomavirus 16 DNA in women who have not experienced sexual
intercourse. Obstetrics and Gynecology, 1994, 83: 735–737.
127. Castellsagué X, de Sanjosé S. Transmission des HPV. In: Aubin F, Prétet J-L,
Mougin CH (eds) Papillomavirus Humains. Biologie et Pathologie Tumorale.
Paris, Editons Tec & Doc, Editions Médicales Internationales, 2003: 309–333.
128. Moscicki AB, Hills N, Shiboski S et al. Risks for incident human
papillomavirus infection and low-grade squamous intraepithelial lesion
development in young females. Journal of the American Medical Association,
2001, 285: 2995–3002.
129. Bauer HM, Ting Y, Greer CE et al. Genital human papillomavirus infection in
female university students as determined by a PCR-based method. Journal of
the American Medical Association, 1991, 265: 472–477.
130. Karlsson R, Jonsson M, Edlund K et al. Lifetime number of partners as the only
independent risk factor for human papillomavirus infection: a population-based
study. Sexually Transmitted Diseases, 1995, 22: 119–127.
131. Ley C, Bauer HM, Reingold A et al. Determinants of genital human
papillomavirus infection in young women. Journal of the National Cancer
Institute, 1991, 83: 997–1003.
132. Schiffman MH, Bauer HM, Hoover RN et al. Epidemiologic evidence showing
that human papillomavirus infection causes most cervical intraepithelial
neoplasia. Journal of the National Cancer Institute, 1993, 85: 958–964.
133. Bosch FX, Muñoz N, de Sanjosé S et al. Risk factors for cervical cancer in
Colombia and Spain. International Journal of Cancer, 1992, 52: 750–758.
134. Bosch FX, Muñoz N, de Sanjosé S et al. Human papilloma virus and cervical
intraepithelial neoplasia grade III/carcinoma in situ:a case–control study
in Spain and Colombia. Cancer Epidemiology Biomark Preview, 1993, 2:
415–422.
135. Chichareon S, Herrero R, Muñoz N et al. Risk factors for cervical cancer in
Thailand: a case–control study. Journal of the National Cancer Institute, 1998,
90: 50–57.
136. Eluf-Neto J, Booth M, Muñoz N et al. Human papillomavirus and invasive
cervical cancer in Brazil. British Journal of Cancer, 1994, 69: 114–119.
137. Franceschi S, Castellsague X, dal Maso L et al. Prevalence and determinants
of human papillomavirus genital infection in men. British Journal of Cancer,
2002, 86: 705–711.
138. Muñoz N, Bosch FX, de Sanjosé S et al. The causal link between human
papillomavirus and invasive cervical cancer: a population-based case-control
study in Colombia and Spain. International Journal of Cancer, 1992, 52:
743–749.
139. Muñoz N, Bosch FX, de Sanjosé S et al. Risk factors for cervical intraepithelial
neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer
Epidemiology Biomark Preview, 1993, 2: 423–431.
140. Muñoz N, Castellsagué X, Bosch FX et al. Difficulty in elucidating the male
role in cervical cancer in Colombia, a high-risk area for the disease. Journal of
the National Cancer Institute, 1996, 88(15): 1068–1075.
141. Ngelangel C, Muñoz N, Bosch FX et al. Causes of cervical cancer in the
Philippines: a case–control study. Journal of the National Cancer Institute,
1998, 90: 43–49.
142. de Sanjosé S, Bosch FX, Valls I et al. Prevalence of HPV cervical infections
among imprisoned women in Barcelona, Spain (Letter to the Editor). Sexually
Transmitted Infections, 2000, 76: 58–66.
143. de Sanjose S, Almirall R, Lloveras B et al. Cervical human papillomavirus
infection in the female population in Barcelona, Spain. Sexually Transmitted
Diseases, 2003, 30: 788–793.
144. Kjaer SK, Svare EI, Worm AM et al. Human papillomavirus infection in Danish
female sex workers. Decreasing prevalence with age despite continuously high
sexual activity. Sexually Transmitted Diseases, 2000, 27: 438–445.
145. Touze A, de Sanjose S, Coursaget P et al. Prevalence of anti-human
papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the
general population and in prostitutes. Journal of Clinical Microbiology, 2001,
39: 4344–4348.
146. Dillner J, Andersson-Ellstrom A, Hagmar B, Schiller J. High risk genital
papillomavirus infections are not spread vertically. Review of Medical Virology,
1999, 9: 23–29.
147. af Geijersstam Va, Kibur M, Wang Z et al. Stability over time of serum
antibody levels to human papillomavirus type 16. Journal of Infectious
Diseases, 1998, 177: 1710–1714.
148. Pridan H, Lilienfeld AM. Carcinoma of the cervix in Jewish women in Israel,
1960–67: an epidemiological study. Israeli Journal of Medical Science, 1971,
7: 1465–1470.
149. Buckley JD, Harris RWC, Doll R et al. Case–control study of the husbands
of women with dysplasia or carcinoma of the cervix uteri. Lancet, 1981, ii:
1010–1015.
150. Kessler II. Venereal factors in human cervical cancer: evidence from marital
clusters. Cancer, 1977, 39: 1912–1919.
151. Graham S, Priore R, Browne R et al. Genital cancer in wives of penile cancer
patients. Cancer, 1979, 44: 1870–1874.
152. Martinez I. Relationship of squamous cell carcinoma of the cervix uteri to
squamous cell carcinoma of the penis among Puerto Rican women married to
men with penile carcinoma. Cancer, 1969, 24: 777–780.
153. Smith PG, Kinlen LJ, White GC et al. Mortality of wives of men dying with
cancer of the penis. British Journal of Cancer, 1980, 41: 422–428.
154. Cartwright RA, Sinson J.D. Carcinoma of penis and cervix. Lancet, 1980, i: 97.
155. Li JY, Li FP, Blot WJ et al. Correlation between cancers of the uterine cervix
and penis in China. Journal of the National Cancer Institute, 1982, 69:
1063–1065.
156. MacGregor JE, Innes G. Carcinoma of penis and cervix. Lancet, 1980, i:
1246–1247.
157. Bosch FX, Cardis E. Cancer incidence correlations. Genital, urinary and some
tobacco-related cancers. International Journal of Cancer, 1990, 46: 178–184.
158. Hemminki K, Dong C. Cancer in husband of cervical cancer patients.
Epidemiology, 2000, 11: 347–349.
159. Hemminki K, Dong C, Vaittinen P. Second primary cancer after in situ and
invasive cervical cancer. Epidemiology, 2000, 11: 457–461.
160. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract
cancers among cervical cancer patients and their husbands. European Journal
of Cancer Prevention, 2000, 9: 433–437.
161. Herrero R, Hildesheim A, Bratti C et al. Population-based study of human
papillomavirus infection and cervical neoplasia in rural Costa Rica. Journal of
the National Cancer Institute, 2000, 92(6): 464–474.
162. Brinton LA, Reeves WC, Brenes MM et al. The male factor in the etiology of
cervical cancer among sexually monogamous women. International Journal of
Cancer, 1989, 44: 199–293.
163. Zunzunegui MV, King MC, Coria CF, Charlet J. Male influences on cervical
cancer risk. American Journal of Epidemiology, 1986, 123: 302–307.
164. Campion MJ, Clarkson P, McCance DJ. Squamous neoplasia of the cervix in
relation to other genital tract neoplasia. Clinical Obstetrics and Gynaecology,
1985, 12: 265–280.
165. Muñoz N, Bosch FX, Chichareon S et al. A multinational case–control study
on the risk of cervical cancer linked to 25 HPV types: which are the high-risk
types? In: Castellsagué X, Bosch FX, de Sanjosé S et al (eds) International
Papillomavirus Conference – Program and Abstracts Book. Barcelona, Thau
S.L., 2000: 125 (available on line: http:/www.hpv2000.com).
166. Baken LA, Koutsky LA, Kuypers J et al. Genital human papillomavirus
infection among male and female sex partners: prevalence and type-specific
concordance. Journal of Infectious Diseases, 1995, 171: 429–432.
167. Hippelainen MI, Yliskoski M, Syrjanen S et al. Low concordance of genital
human papillomavirus (HPV) lesions and viral types in HPV-infected women
and their male sexual partners. Sexually Transmitted Diseases, 1994, 21: 76–82.
168. Kyo S, Inoue M, Koyama M et al. Detection of high-risk human papillomavirus
in the cervix and semen of sex partners. Journal of Infectious Diseases, 1994,
170: 682–685.
169. Strand A, Rylander E, Wilander E, Zehbe I. Human papilloma virus infection in
male partners of women with squamous intraepithelial neoplasia and/or highrisk
human papilloma virus. Acta Dermatologica Venereologia (Stockh), 1995,
75: 312–316.
170. Hippelainen MI, Hippelainen M, Saarikoski S, Syrjanen K. Clinical course
and prognostic factors of human papillomavirus infections in men. Sexually
Transmitted Diseases, 1994, 21: 272–279.
171. Mant C, Cason J, Rice P, Best JM. Non-sexual transmission of cervical cancerassociated
papillomaviruses: an update. Papillomavirus Report, 2000, 11: 1–5.
172. Hajek EF. Contribution to the etiology of laryngeal papilloma in children.
Journal of Laryngology and Otology, 1956, 70: 166–168.
173. Cason J, Kaye JN, Jewers RJ et al. Perinatal infection and persistence of human
papillomavirus types 16 and 18 in infants. Journal of Medical Virology, 1995,
47: 209–218.
174. Chen S, Slavin J, Fairley CK et al. The absence of HPV DNA in genital
specimens from infants. Genitourinary Medicine, 1993, 69: 270–272.
175. Fredericks BD, Balkin A, Daniel HW et al. Transmission of human
papillomaviruses from mother to child. Australia and New Zealand Journal of
Obstetrics and Gynaecology, 1993, 33: 30–32.
176. Kaye JN, Starkey WG, Kell B et al. Human papilloma virus type 16 in infants:
use of DNA sequence analyses to determine the source of infection. Journal of
General Virology, 1996, 77: 1139–1143.
177. Koch A, Hansen SV, Nielsen NM et al. HPV detection in children prior to
sexual debut. International Journal of Cancer, 1997, 73: 621–624.
178. Pakarian F, Kaye J, Cason J et al. Cancer associated human papillomaviruses:
perinatal transmission and persistence. British Journal of Obstetrics and
Gynaecology, 1994, 101: 514–517.
179. Puranen M, Yliskoski M, Saarikoski S et al. Vertical transmission of human
papillomavirus from infected mothers to their newborn babies and persistence
of the virus in childhood. American Journal of Obstetrics and Gynecology,
1996, 174: 694–699.
180. Smith EM, Johnson SR, Cripe T et al. Perinatal transmission and maternal risks
of human papillomavirus infection. Cancer Detection and Prevention, 1995,
19: 196–205.
181. Tseng CJ, Liang CH, Soong YK, Pao CC. Perinatal transmission of human
papillomavirus in infants: relationship between infection rate and mode of
delivery. Obstetrics and Gynecology, 1998, 91: 92–96.
182. Watts DH, Koutsky LA, Holmes KK et al. Low risk of perinatal transmission
of human papillomavirus: results from a prospective cohort study. American
Journal of Obstetrics and Gynecology, 1998, 178: 365–372.
183. Aaltonen LM, Rihkanen H, Vaheri A. Human papillomavirus in larynx.
Laryngoscope, 2002, 112: 700–707.
184. Kashima HK, Shah F, Lyles A et al. A comparison of risk factors in juvenileonset
and adult-onset recurrent respiratory papillomatosis. Laryngoscope, 1992,
102: 9–13.
185. Armbruster-Moraes E, Ioshimoto LM, Leao E, Zugaib M. Presence of human
papillomavirus DNA in amniotic fluids of pregnant women with cervical
lesions. Gynecologic Oncology, 1994, 52: 152–158.
186. Favre M, Majewski S, De Jesus N et al. A possible vertical transmission
of human papillomavirus genotypes associated with epidermodysplasia
verruciformis. Journal of Investigative Dermatology, 1998, 111: 333–336.
187. Tseng CJ, Lin CY, Wang RL et al. Possible transplacental transmission of
human papillomaviruses. American Journal of Obstetrics and Gynecology,
1992, 166: 35–40.
188. Fleming KA, Venning V, Evans M. DNA typing of genital warts and diagnosis
of sexual abuse of children. Lancet, 1987, 2: 454.
189. Lacey CJN. Genital warts in children. In: Lacey CJN, Lacey C (eds)
Papillomavirus Reviews: Current Research on Papillomaviruses. Leeds
University Press, 1996: 291–296.
190. Sonnex C, Strauss S, Gray JJ. Detection of human papillomavirus DNA on the
fingers of patients with genital warts. Sexually Transmitted Infections. 1999, 75:
317–319.
191. Newton R. A review of the aetiology of squamous cell carcinoma of the
conjunctiva. British Journal of Cancer, 1996, 74: 1511–1513.
192. Newton R, Ziegler J, Ateenyi-Agaba C et al. The epidemiology of conjunctival
squamous cell carcinoma in Uganda. British Journal of Cancer, 2002, 87:
301–308.
193. Armstrong DK, Handley JM. Anogenital warts in prepubertal children:
pathogenesis, HPV typing and management. International Journal of STD and
AIDS, 1997, 8: 78–81.
194. Bergeron C, Ferenczy A, Richart R. Underwear: contamination by human
papillomaviruses. American Journal of Obstetrics and Gynecology, 1990, 162:
25–29.
195. Ferenczy A, Bergeron C, Richart RM. Human papilloma virus DNA in
fomites on objects used for the management of patients with genital human
papillomavirus infections. Obstetrics and Gynecology, 1989, 74: 950–954.
196. Liu Y, Klimberg VS, Andrews NR et al. Human papillomavirus DNA is present
in a subset of unselected breast cancers. Journal of Human Virology, 2001, 4:
329–334.
197. Yu Y, Morimoto T, Sasa M et al. Human papillomavirus type 33 DNA in breast
cancer in Chinese. Breast Cancer, 2000, 7: 33–36.
198. Manavi M, Baghestanian M, Kucera E et al. Papilloma virus and c-erbB-2
expression in diseases of the mammary nipple. Anticancer Research, 2001, 21:
797–801.
199. Chan PJ, Su BC, Kalugdan T et al. Human papillomavirus gene sequences in
washed human sperm deoxyribonucleic acid. Fertility and Sterility, 1994, 61:
982–985.
200. Lai YM, Lee JF, Huang HY et al. The effect of human papillomavirus infection
on sperm cell motility. Fertility and Sterility, 1997, 67, 1152–1155.
201. Nieminen P, Koskimies AI, Paavonen J. Human papillomavirus DNA is not
transmitted by semen. International Journal of STD and AIDS, 1991, 2:
207–208.
202. Olatunbosun O, Deneer H, Pierson R. Human papillomavirus DNA detection in
sperm using polymerase chain reaction. Obstetrics and Gynecology, 2001, 97:
357–360.
203. Ostrow RS, Zachow KR, Niimura M et al. Detection of papillomavirus DNA in
human semen. Science, 1986, 231: 731–733.
204. Jacobs MV, Walboomers JMM, Snijders PJF et al. Distribution of 37
mucosotropic HPV types in women with cytologically normal cervical smears:
the age-related patterns for high-risk and low types. International Journal of
Cancer, 2000, 87: 221–227.
205. Parkin DM, Whelan SL, Ferlay J et al. (eds) Cancer Incidence in Five
Continents, vol. VII. Lyon, International Agency for Research on Cancer, 1997.
206. Lazcano-Ponce E, Herrero R, Munoz N et al. Epidemiology of HPV infection
among Mexican women with normal cervical cytology. International Journal
Cancer, 2001, 91: 412–420.
207. Melkert PWJ, Hopman E, Van den Brule AJC et al. Prevalence of HPV in
cytomorphologically normal cervical smears, as determined by the polymerase
chain reaction, is age-dependent. International Journal of Cancer, 1993, 53:
919–923.
208. Schneider A, Hoyer H, Lotz B et al. Screening for high-grade cervical intraepithelial
neoplasia and cancer by testing for high-risk HPV, routine cytology or
colposcopy. International Journal of Cancer, 2000, 89: 529–534.
209. Franco EL, Villa LL, Sobrinho JP et al. Epidemiology of acquisition and
clearance of cervical human papillomavirus infection in women from a
high-risk area for cervical cancer. Journal of Infectious Diseases, 1999, 180:
1415–1423.
210. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginal
papillomavirus infection in young women. New England Journal of Medicine,
1998, 338: 423–428.
211. Woodman CB, Collins S, Winter H et al. Natural history of cervical human
papillomavirus infection in young women: a longitudinal cohort study. Lancet,
2001, 357: 1831–1836.
212. Ho GY, Burk RD, Klein S et al. Persistent genital human papillomavirus
infection as a risk factor for persistent cervical dysplasia .
Journal of the National Cancer Institute, 1995, 87: 1365–1371.
213. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of
cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus
infection. New England Journal of Medicine, 1992, 327: 1272–1278.
214. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human
papillomavirus status to cervical lesions and consequences for cervical-cancer
screening: a prospective study. Lancet, 1999, 354: 20–25.
215. Remmink AJ, Walboomers JM, Helmerhorst TJ et al. The presence of persistent
high-risk HPV genotypes in dysplastic cervical lesions is associated with
progressive disease: natural history up to 36 months. International Journal of
Cancer, 1995, 61: 306–311.
216. Rozendaal L, Walboomers JM, van der Linden JC et al. PCR-based high-risk
HPV test in cervical cancer screening gives objective risk assessment of women
with cytomorphologically normal cervical smears. International Journal
Cancer, 1996, 68: 766–769.
217. Rozendaal L, Westerga J, van der Linden JC et al. PCR based high risk HPV
testing is superior to neutral network based screening for predicting incident
CIN III in women with normal cytology and borderline changes. Journal of
Clinical Pathology, 2000, 53: 606–611.
218. Nobbenhuis MA, Helmerhorst TJM, Van den Brule AJC et al. Cytological
regression and clearance of high-risk human papillomavirus in women with an
abnormal cervical smear. Lancet, 2002, 358: 1782–1783.
219. Zielinski GD, Snijders PJF, Rozendaal L et al. HPV presence precedes
abnormal cytology in women developing cervical cancer and signals false
negative smears. British Journal of Cancer, 2001, 85(3): 398–404.
220. Manos MM, Kinney WK, Hurley LB et al. Identifying women with cervical
neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou
results. Journal of the American Medicine Association, 1999, 281(17): 1605–
1647.
221. Schlecht NF, Kulaga S, Robitaille J et al. Persistent human papillomavirus
infection as a predictor of cervical intraepithelial neoplasia. Journal of the
American Medicine Association, 2001, 286: 3106–3114.
222. Zielinski GD, Snijders PJF, Rozendaal L et al. High-risk HPV testing in women
with borderline and mild dyskaryosis: long-term follow-up data and clinical
relevance. Journal of Pathology, 2001, 193: 1–8.
223. Nobbenhuis MAE, Meijer CJLM, Van den Brule AJC et al. Addition of highrisk
HPV testing improves the current guidelines on follow-up after treatment
for cervical intraepithelial neoplasia. British Journal of Cancer, 2001, 84(6):
796–801.
224. Wallin et al. 1999.
225. Dillner J, Lehtinen M, Björge T et al. Prospective seroepidemilogic study of
human papillomavirus infection as a risk factor for invasive cervical cancer.
Journal of the National Cancer Institute, 1997, 89: 1293–1299.
226. Campion MJ, McCance DJ, Cuzick J, Singer A. Progressive potential of mild
cervical atypia: prospective cytological, colposcopic, and virological study.
Lancet, 1986, 2: 237–240.
227. Cuzick J, Terry G, Ho L et al. Human papilloma virus type 16 DNA in cervical
smears as predictor of high-grade cervical cancer. Lancet, 1992, 339: 959–960.
228. Cuzick J, Terry G, Ho L et al. Type-specific human papillomavirus DNA in
abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia.
British Journal of Cancer, 1994, 69: 167–171.
229. Cuzick J, Szarewski A, Terry G et al. Human papilloma virus testing in primary
cervical screening. Lancet, 1995, 345, 1533–1536.
230. Cuzick J, Sasieni, P, Davies P et al. A systematic review of the role of human
papilloma virus (HPV) testing within a cervical screening programme:
summary and conclusions. British Journal of Cancer, 2000, 83, 561–565.
231. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary
screening of cervical cancer precursors. Cancer Epidemiology Biomark
Preview, 2000, 9: 945–951.
232. International Agency for Research on Cancer IARC Handbook of Cancer
Prevention. Volume 10. Cervical Cancer Screening. Lyon, IARC Press 2005.
233. Clavel C, Masure M, Bory JP et al. Hybrid capture II-based human
papillomavirus detection, a sensitive test to detect in routine high-grade cervical
lesions: a preliminary study on 1518 women. British Journal of Cancer, 1999,
80(9): 1306–1311.
234. Solomon D, Schiffman M, Tarone R and the ALTS Group. Comparison of
three management strategies for patients with atypical squamous cells of
undetermined significance: baseline results from a randomized trial. Journal of
the National Cancer Institute, 2001, 93: 293–299.
235. Schiffman M, Herrero R, Hidesheim A et al. HPV DNA testing in cervical
cancer screening. Results from women in a high-risk province of Costa Rica.
Journal of the American Medical Association, 2000, 283: 87–93.
236. Wright Jr TC, Denny L, Kuhn L et al. HPV DNA testing of self-collected
vaginal samples compared with cytologic screening to detect cervical cancer.
Journal of the American Medical Association, 2000, 282: 81–86.
237. Gravitt PE, Manos MM. Polymerase chain reaction-based methods for the
detection of human papillomavirus DNA. In: Muñoz N, Bosch FX, Shah KV,
Meheus A (eds) The Epidemiology of Human Papillomavirus and Cervical
Cancer. IARC Scientific Publications, no. 119. Lyon, International Agency for
Research on Cancer, 1992: 121–133.
238. Bosch FX, Rohan T, Schneider A et al. Papillomavirus research update:
highlights of the Barcelona HPV 2000 international papillomavirus conference.
Journal of Clinical Pathology, 2001 54: 163–175.
239. Chaouki N, Bosch FX, Muñoz N et al. The viral origin of cervical cancer in
Rabat, Morocco. International Journal of Cancer, 1998, 75: 546–554.
240. Rolón PA, Smith JS, Muñoz N et al. Human papillomavirus infection and
invasive cervical cancer in Paraguay. International Journal of Cancer, 2000,
85: 486–491.
241. Santos C, Muñoz N, Klug S et al. HPV types and cofactors causing cervical
cancer in Peru. British Journal of Cancer, 2001, 85: 966–971.
242. Thomas DB, Qin Q, Kuypers J et al. Human papillomaviruses and cervical
cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell
cervical carcinomas. American Journal of Epidemiology, 2001, 153(8):
732–739.
243. Olsen AO, Gjoen K, Sauer T et al. Human papilloma virus and cervical
intraepithelial neoplasia grade II-III: A population–based case–control study.
International Journal of Cancer, 1995, 61: 312–315.
244. Kjaer SK, Van den Brule AJC, Bock JE et al. Human papilloma virus – the
most significant risk determinant of cervical intraepithelial neoplasia.
International Journal of Cancer, 1996, 65: 601–606.
245. Castellsagué X, Menendez C, Loscertales MP et al. Human papillomavirus
genotypes in rural Mozambique. Lancet, 2001, 358: 1429–1430.
246. de Sanjosé S, Valls I, Cañadas MP et al. Infección por el virus del papiloma
humano y de la inmunodeficiencia humana como factores de riesgo para el
cáncer de cuello uterino en mujeres reclusas. Med. Clin. (Barc.), 2000, 115:
81–84.
247. Palefsky JM, Minkoff H, Kalish LA et al. Cervicovaginal human
papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive
and high-risk HIV-negative women. Journal of the National Cancer Institute,
1999, 91(3): 226–236.
248. Bosch FX, Muñoz N, Chichareon S et al. HPV and cervical adenocarcinoma: an
IARC based multicentric case–control study. In: Castellsagué X, Bosch FX, de
Sanjose et al (eds) 18th International Papillomavirus Conference Program and
Abstracts Book. Barcelona, Thau SL: 131, 2000, (available on line: http:/www.
hpv2000.com).
259. Josefsson AM, Magnusson PK, Ylitalo N et al. Viral load of human papilloma
virus 16 as a determinant for development of cervical carcinoma in situ: a
nested case–control study. Lancet, 2000, 355: 2189–2193.
250. Thomas DB, Ray RM, Koetsawang A et al. Human papillomaviruses and
cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas
with human papillomavirus types 16 and 18 DNA. American Journal of
Epidemiology, 2001, 153(8): 723–731.
251. Ylitalo N, Josefsson A, Melbye M et al. A prospective study showing long-term
infection with human papillomavirus 16 before the development of cervical
carcinoma in situ. Cancer Research, 2000, 60: 6027–6032.
252. Moreno V, Muñoz N, Bosch FX et al. Risk factors for progression of cervical
intraepithelial neoplasm grade III to invasive cervical cancer. Cancer
Epidemiology Biomark Preview, 1995, 4: 459–467.
253. Riou G, Favre M, Jeannel D, Bourhis J et al. Association between poor
prognosis in early-stage invasive cervical carcinomas and non-detection of
HPV DNA. Lancet, 1990, 335: 1171–1174.
254. Viladiu P, Bosch FX, Castellsagué X et al. Human papillomavirus DNA and
antibodies to human papilloma virus 16 E2, L2 and E7 peptides as predictors
of survival in patients with squamous cell cervical cancer. Journal of Clinical
Oncology, 1997, 15: 610–619.
255. Burger, MPM, Hollema H, Pieters M et al. Epidemiological evidence
of cervical intraepithelial neoplasia without the presence of human
papillomavirus. British Journal of Cancer, 1996, 73: 831–836.
256. Tabrizi SN, Fairley CK, Chen S et al. Epidemiological characteristics of
women with high grade CIN who do and do not have human papillomavirus.
British Journal of Obstetrics and Gynaecology, 1999, 106: 252–257.
257. Castellsagué X, Muñoz N. Cofactors in human papillomavirus carcinogenesis–
role of parity, oral contraceptives, and tobacco smoking. Journal of the
National Cancer Institute Monographs, 2003, 31: 20–28.
258. Smith JS, Herrero R, Bosetti C et al. Herpes simplex virus-2 as a human
papillomavirus cofactor in the etiology of invasive cervical cancer. Journal of
the National Cancer Institute, 2002, 94: 1604–1613.
259. Smith JS, Bosetti C, Munoz N et al. Chlamydia trachomatis and invasive
cervical cancer: a pooled analysis of the IARC multicentric case–control study.
International Journal Cancer, 2004, 111: 431–439.
260. Bayo S, Bosch FX, de Sanjose S et al. Risk factors of invasive cervical cancer
in Mali. International Journal of Epidemiology, 2002, 31: 202–209.
261. de Sanjose S, Palefsky J. Cervical and anal HPV infections in HIV positive
women and men. Virus Research, 2002, 89: 201–211.
262. Gichangi P, De Vuyst H, Estambale B et al. HIV and cervical cancer in Kenya.
International Journal of Gynaecology and Obstetrics, 2002, 76: 55–63.
263. International Agency for Research on Cancer. IARC Monograph on Human
Immunodeficiency Virus. Lyon, IARC Press,1996.
264. Massad LS, Riester KA, Anastos KM et al. Prevalence and predictors of
squamous cell abnormalities in Papanicolaou smears from women infected with
HIV-1. Women’s Interagency HIV Study Group. Journal of Acquired Immune
Deficiency Syndrome, 1999, 21: 33–41.
265. Ahdieh L, Munoz A, Vlahov D et al. Cervical neoplasia and repeated positivity
of human papillomavirus infection in human immunodeficiency virus:
seropositive and seronegative women. American Journal of Epidemiology,
2000, 151: 1148–1157.
266. Mandelblatt JS, Kanetsky P, Eggert L, Gold K. Is HIV infection a cofactor for
cervical squamous cell neoplasia? Cancer Epidemiology Biomark Preview,
1999, 8: 97–106.
267. Sun XW, Kuhn L, Ellerbrock TV et al. Human papilloma virus infection
in women infected with the human immunodeficiency virus. New England
Journal of Medicine, 1997, 337: 1343–1349.
268. Ellerbrock TV, Chiasson MA, Bush TJ et al. Incidence of cervical squamous
intraepithelial lesions in HIV-infected women. Journal of the American
Medical Association, 2000, 283: 1031–1037.
269. International Collaboration on HIV and Cancer. Highly active antiretroviral
therapy and incidence of cancer in human immnodeficiency virus-infected
adults. Journal of the National Cancer Institute, 2000, 92: 1823–1830.
270. Newton R, Beral V, Weiss RA. Human immunodeficiency virus infection and
cancer. In: Newton R, Beral V, Weiss RA (eds) Cancer Surveys. Infections and
Human Cancer. USA Imperial Cancer Research Fund, Cold Spring Harbor
Laboratory Press, 1999: 237–262.
271. Sitas F, Pacella-Norman R, Carrara H et al. The spectrum of HIV-1 related
cancers in South Africa. International Journal Cancer, 2000, 88: 489–492.
272. Selik RM, Rabkin CS. Cancer death rates associated with human
immunodeficiency virus infection in the United States. Journal of the National
Cancer Institute, 1998, 90: 1300–1302.
273. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers
in patients with human immunodeficiency virus infection and acquired
immunodeficiency syndrome. Journal of the National Cancer Institute, 2000,
92: 1500–1510.
274. Gallagher B, Wang Z, Schymura MJ et al. Cancer incidence in New York
State acquired immunodeficiency syndrome patients. American Journal of
Epidemiology, 2001, 154: 544–556.
275. Franceschi S, dal Maso L, Arniani S et al. Risk of cancer other than Kaposi’s
sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer
and AIDS Registry Linkage Study. British Journal of Cancer, 1998, 78:
966–970.
276. Serraino D, Carrieri P, Pradier C et al. Risk of invasive cervical cancer among
women with, or at risk for, HIV infection. International Journal of Cancer,
1999, 82: 334–337.
277. Vall Mayans et al. 1999.
278. Strickler HD, Palefsky JM, Shah KV et al. Human papillomavirus type 16 and
immune status in human immunodeficiency virus-seropositive women. Journal
of the National Cancer Institute, 2003, 95: 1062–1071.
279. Castle PE, Wacholder S, Lorincz AT et al. A prospective study of high-grade
cervical neoplasia risk among human papillomavirus-infected women. Journal
of the National Cancer Institute, 2002, 94: 1406–1414.
280. Rous P. Transmission of a malignant new growth by mean of a cell-free filtrate.
Journal of the American Medical Association, 1911, 56: 198.
281. Yang X, Jin G, Nakao Y et al. Malignant transformation of HPV 16-
immortalized human endocervical cells by cigarette smoke condensate and
characterization of multistage carcinogenesis. International Journal of Cancer,
1996, 65: 338–344.
282. Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE. Identification of tobaccospecific
carcinogen in the cervical mucus of smokers and nonsmokers. Journal
of the National Cancer Institute, 1997, 89(12): 868–873.
283. Poppe WA, Ide PS, Drijkoningen MP et al. Tobacco smoking impairs the local
immunosurveillance in the uterine cervix. An immunohistochemical study.
Gynecology and Obstetrics Investigations, 1995, 39: 34–38.
284. Guiliano AR, Sedjo RL, Roe DJ et al. Clearance of oncogenic human
papillomavirus (HPV) infection: effect of smoking (United States). Cancer
Causes Control, 2002, 13: 839–846.
285. Szarewski A, Jarvis MJ, Sasieni P et al. Effect of smoking cessation on cervical
lesion size. Lancet, 1996, 347: 941–943.
286. Smith JS, Green J, Berrington DG et al. Cervical cancer and use of hormonal
contraceptives: a systematic review. Lancet, 2003, 361: 1159–1167.
287. Munoz N, Franceschi S, Bosetti C et al. Role of parity and human
papillomavirus in cervical cancer: the IARC multicentric case–control study.
Lancet, 2002, 359: 1093–1101.
288. Hildesheim A, Herrero R, Castle PE et al. HPV co-factors related to the
development of cervical cancer: results from a population-based study in Costa
Rica. British Journal of Cancer, 2001, 84(9): 1219–1226.
289. Deacon J, Peto J, Yule R et al. Sexual behaviour and smoking as determinants
of cervical HPV infection and of CIN3 among those infected: a case–control
study nested within the Manchester cohort. British Journal of Cancer, 2000,
88: 1565–1572.
290. Kjaer SK, Van den Brule AJC, Svare EI et al. Different risk factor patterns for
high-grade and low-grade intraepithelial lesions on the cervix among HPVpositive
and HPV-negative young women. International Journal Cancer, 1998,
76: 613–619.
291. García-Closas R, Castellsagué X, Bosch X, González CA. The role of diet and
nutrition in cervical carcinogenesis: a review of recent evidence. International
Journal of Cancer, 2005.
292. Follen M, Meyskens Jr FL, Atkinson EN Schottenfeld D. Why most
randomized phase II cervical cancer chemoprevention trials are uninformative:
lessons for the future. Journal of the National Cancer Institute, 2001, 93:
1293–1296.
293. Giuliano AR, Siegel EM, Roe DJ et al. Dietary intake and risk of persistent
human papillomavirus (HPV) infection: the Ludwig–McGill HPV natural
history study. Journal of Infectious Diseases, 2003, 188: 1508–1516.
294. Sedjo RL, Roe DJ, Abrahamsen M et al. Vitamin A, carotenoids, and risk of
persistent oncogenic human papillomavirus infection. Cancer Epidemiology
Biomark Preview, 2002, 11: 876–884.
295. Goodman MT, Kiviat N, McDuffie K et al. The association of plasma
micronutrients with the risk of cervical dysplasia in Hawaii. Cancer
Epidemiology Biomark Preview, 1998, 7: 537–544.
296. Nagata C, Shimizu H, Yoshikawa H et al. Serum carotenoids and vitamins and
risk of cervical dysplasia from a case–control study in Japan. British Journal of
Cancer, 1999, 81: 1234–1237.
297. Giuliano AR, Papenfuss M, Nour M et al. Antioxidant nutrients: associations
with persistent human papillomavirus infection. Cancer Epidemiology Biomark
Preview, 1997, 6: 917–923.
298. Ho GY, Palan PR, Basu J et al. Viral characteristics of human papillomavirus
infection and antioxidant levels as risk factors for cervical dysplasia.
International Journal of Cancer, 1998, 78: 594–599.
299. Shannon J, Thomas DB, Ray RM et al. Dietary risk factors for invasive and insitu
cervical carcinomas in Bangkok, Thailand. Cancer Causes Control, 2002,
13: 691–699.
300. Wideroff L, Potischman N, Glass AG et al. A nested case–control study of
dietary factors and the risk of incident cytological abnormalities of the cervix.
Nutrition and Cancer, 1998, 30: 130–136.
301. Yeo AS, Schiff MA, Montoya G et al. Serum micronutrients and cervical
dysplasia in Southwestern American Indian women. Nutrition and Cancer,
2000, 38: 141–150.
302. Alberg AJ, Selhub J, Shah KV et al. The risk of cervical cancer in relation
to serum concentrations of folate, vitamin B12, and homocysteine. Cancer
Epidemiology Biomark Preview, 2000, 9: 761–764.
303. Goodman MT, McDuffie K, Hernandez B et al. Case–control study of plasma
folate, homocysteine, vitamin B(12), and cysteine as markers of cervical
dysplasia. Cancer, 2000, 89: 376–382.
304. Sedjo RL, Inserra P, Abrahamsen M et al. Human papillomavirus persistence
and nutrients involved in the methylation pathway among a cohort of young
women. Cancer Epidemiology Biomark Preview, 2002, 11: 353–359.
305. Sedjo RL, Fowler BM, Schneider A et al. Folate, vitamin B12, and
homocysteine status. findings of no relation between human papillomavirus
persistence and cervical dysplasia. Nutrition, 2003, 19: 497–502.
306. Montoya L, Saiz I, Rey G et al. Cervical carcinoma: human papillomavirus
infection and HLA-associated risk factors in the Spanish population. European
Journal of Immunogenetics, 1998, 25: 329–337.
307. Bontkes HJ, Walboomers JM, Meijer CJ et al. Specific HLA class I downregulation
is an early event in cervical dysplasia associated with clinical
progression. Lancet, 1998, 351: 187–188.
308. Duggan-Keen MF, Keating PJ, Stevens FR et al. Immunogenetic factors in
HPV-associated cervical cancer: influence on disease progression. European
Journal of Immunogenetics, 1996, 23: 275–284.
309. Ellis JR, Keating PJ, Baird J et al. The association of an HPV16 oncogene
variant with HLA-B7 has implications for vaccine design in cervical cancer.
Nature Medicine, 1995, 1: 464–470.
310. Yamada T, Wheeler CM, Halpern AL et al. Human papilloma virus type 16
variant lineages in United States populations characterized by nucleotide
sequence analysis of the E6, L2 and L1 coding segments. Journal of Virology,
1995, 69: 7743–7753.
311. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a
review. Virus Research, 2002, 89: 229–240.
312. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the
development of human papillomavirus-associated cancer. Nature, 1998, 393:
229–234.
313. Zehbe I, Voglino G, Wilander E et al. p53 Codon 72 polymorphism and various
human papillomavirus 16 E6 genotypes are risk factors for cervical cancer
development. Cancer Research, 2001, 61: 608–611.
314. Giannoudis A, Graham DA, Southern SA, Herrington CS. p53 codon 72 ARG/
PRO polymorphism is not related to HPV type or lesion grade in low- and highgrade
squamous intra-epithelial lesions and invasive squamous carcinoma of
the cervix. International Journal of Cancer, 1999, 83: 66–69.
315. Hayes VM, Hofstra RM, Buys CH et al. Homozygous arginine-72 in wild type
p53 and risk of cervical cancer. Lancet, 1998, 352: 1756.
316. Helland A, Olsen AO, Gjoen K et al. An increased risk of cervical intraepithelial
neoplasia grade II-III among human papillomavirus positive patients
with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based
case–control study of Norwegian women. International Journal of Cancer,
1998, 76: 19–24.
317. Hildesheim A, Schiffman M, Brinton LA et al. p53 polymorphism and risk of
cervical cancer. Nature, 1998, 396: 531–532.
318. Josefsson AM, Magnusson PK, Ylitalo N et al. p53 polymorphism and risk of
cervical cancer. Nature, 1998, 396: 531.
319. Klaes R, Ridder R, Schaefer U et al. No evidence of p53 allele-specific
predisposition in human papillomavirus-associated cervical cancer. Journal of
Molecular Medicine, 1999, 77: 299–302.
320. Lanham S, Campbell I, Watt P, Gornall R. p53 polymorphism and risk of
cervical cancer. Lancet, 1998, 352: 1631.
321. Minaguchi T, Kanamori Y, Matsushima M et al. No evidence of correlation
between polymorphism at codon 72 of p53 and risk of cervical cancer
in Japanese patients with human papillomavirus 16/18 infection. Cancer
Research, 1998, 58: 4585–4586.
322. Rosenthal AN, Ryan A, Al-Jehani RM et al. p53 codon 72 polymorphism and
risk of cervical cancer in UK. Lancet, 1998, 352: 871–975.
323. Kutler DI, Wreesmann VB, Goberdhan A et al. Human papillomavirus DNA
and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia
patients. Journal of the National Cancer Institute, 2003, 95: 1718–1721.
324. Brady et al. 1999.
325. Goodman MT, McDuffie K, Hernandez B et al. Association of
methylenetetrahydrofolate reductase polymorphism C677T and dietary folate
with the risk of cervical dysplasia. Cancer Epidemiology Biomark Preview,
2001, 10(12): 1275–1280.
326. Harima Y, Sawada S, Nagata K et al. Polymorphism of the WAF1 gene is
related to susceptibility to cervical cancer in Japanese women. International
Journal of Molecular Medicine, 2001, 7: 261–264.
327. Stanczuk GA, Sibanda EN, Perrey C et al. Cancer of the uterine cervix may be
significantly associated with a gene polymorphism coding for increased IL-10
production. International Journal of Cancer, 94, 792–794.
328. Kaufmann AM, Backsch C, Schneider A, Durst M. HPV induced cervical
carcinogenesis: molecular basis and vaccine development. Zentralbl. Gynakol.,
2002, 124: 511–524.
329. Lazo PA. The molecular genetics of cervical carcinoma. British Journal of
Cancer, 1999, 80(12): 2008–2018.
330. Southern SA, Herrington CS. Molecular events in uterine cervical cancer.
Sexually Transmitted Infections, 1998, 74: 101–109.
331. Chan PK, Lam CW, Cheung TH et al. Association of human papillomavirus
type 58 variant with the risk of cervical cancer. Journal of the National Cancer
Institute, 2002, 94: 1249–1253.
332. Hecht JL, Kadish AS, Jiang G, Burk RD. Genetic characterization of the human
papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence
of a subtype with decreased oncogenic potential. International Journal of
Cancer, 1995, 60: 369–376.
333. Lizano M, Berumen J, Guido MC et al. Association between human
papillomavirus type 18 variants and histopathology of cervical cancer. Journal
of the National Cancer Institute, 1997, 89: 1227–1231.
334. Villa LL, Sichero L, Rahal P et al. Molecular variants of human papillomavirus
types 16 and 18 preferentially associated with cervical neoplasia. Journal of
General Virology, 2000, 81: 2959–2968.
335. Xi LF, Koutsky LA, Galloway DA et al. Genomic variation of human
papillomavirus type 16 and risk for high grade cervical intraepithelial
neoplasia. Journal of the National Cancer Institute, 1997, 89: 796–802.
336. Zehbe I, Wilander E, Delius H, Tommasino M. Human papillomavirus 16 E6
variants are more prevalent in invasive cervical carcinoma than the prototype.
Cancer Research, 1998, 58: 829–833.
337. Nindl I, Rindfleisch K, Lotz B et al. Uniform distribution of HPV 16 E6 and
E7 variants in patients with normal histology, cervical intra-epithelial neoplasia
and cervical cancer. International Journal of Cancer, 1999, 82: 203–207.
338. Zehbe I, Voglino G, Delius H et al. Risk of cervical cancer and geographical
variations of human papillomavirus 16 E6 polymorphisms. Lancet, 1998, 352:
1441–1442.
339. Yamada T, Manos MM, Peto J et al. Human papillomavirus type 16 sequence
variation in cervical cancers: a worldwide perspective. Journal of Virology,
1997, 71: 2463–2472.
340. van Duin M, Snijders PJ, Vossen MT et al. Analysis of human papillomavirus
type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in
cervical carcinogenesis. Journal of General Virology, 2000, 81: 317–325.
341. Ylitalo N, Sorensen P, Josefsson AM et al. Consistent high viral load of human
papillomavirus 16 and risk of cervical carcinoma in situ: a nested case–control
study. Lancet, 2000, 355(9222): 2194–2198.
342. Abba MC, Mouron SA, Gomez MA et al. Association of human papillomavirus
viral load with HPV16 and high-grade intraepithelial lesion. International
Journal of Gynecology and Cancer, 2003, 13: 154–158.
343. Swan DC, Tucker RA, Holloway BP, Icenogle JP. A sensitive, type-specific,
fluorogenic probe assay for detection of human papillomavirus DNA. Journal
of Clinical Microbiology, 1997, 35: 886–891.
344. Lorincz AT, Castle PE, Sherman ME et al. Viral load of human papillomavirus
and risk of CIN3 or cervical cancer. Lancet, 2002, 360: 228–229.
345. van Duin M, Snijders PJ, Schrijnemakers HF et al. Human papillomavirus 16
load in normal and abnormal cervical scrapes: an indicator of CIN II/III and
viral clearance. International Journal of Cancer, 2002, 98: 590–595.
346. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control
in early event in carcinogenesis. Journal of the National Cancer Institute, 2000,
92: 690–698 .
347. Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human
papillomavirus from a continuous cell line upon epithelial differentiation.
Science, 1992, 257: 971–973.
348. Fuchs PG, Girardi F, Pfister H. Human papillomavirus 16 DNA in cervical
cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for
early metastases? International Journal of Cancer, 1989, 43: 41–44.
349. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human
papillomavirus type 16 are involved in invasive cervical cancers. Virology,
1989, 172: 63–72.
350. Pirami L, Giache V, Becciolini A. Analysis of HPV16, 18, 31, and 35 DNA
in pre-invasive and invasive lesions of the uterine cervix. Journal of Clinical
Pathology, 1997, 50: 600–604.
351. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of
multiple genes in carcinoma of the uterine cervix. Clinical Cancer Research,
2001, 7: 1982–1986.
352. Virmani AK, Muller C, Rathi A et al. Aberrant methylation during cervical
carcinogenesis. Clinical Cancer Research, 2001, 7: 584–589.
353. Steenbergen RD, Kramer D, Braakhuis BJ et al. TSLC1 gene silencing in
cervical cancer cell lines and cervical neoplasia. Journal of the National Cancer
Institute, 2004, 96: 294–305.

I'm sitting on the sidelines on this argument today.
:yourock:

The mistruths being disseminated with such intensity, consistency, vehemence... I continue to ask WHY?

That's just not considered right, somehow.

Me? I just wanna know if the damned thing works.

One might think that would be the important issue, but it seems to have been lost in some discussions...:shrug:

The efficacy is being tossed aside in a RISK!!!!!!!!!/(benefit) discussion. Geez, life is risk, ain't it?
The Professor

Glad to have you back weighing in again...

Unfortunately to some the motto is "Facts, Facts, we don't need no stinking facts (nor data, or statistics or published studies, or science--just assertions and accusations)

:)

The state mandate, rather than a "we'll pay for it if you want your child to have it" approach is sticking in some people's throats. I actually completely understand that.

The objection to a vaccine because it isn't 100% efficacious seems short-sighted. And, the causation of vaccination to many other illnesses, absent the data regarding the diagnostic enhancements in identifying these maladies is scientifically disingenuous. So, out of the three common objections, i only buy into the first. The rest seem specious.
The Professor

and a state decision whether to include it in school entry requirements.. Those who argue against a mandate should be addressing this with their state houses and state representatives..

Having said that, if the goal is to reduce cervical cancer among women, vaccinating a handful of females (and eventually males) will not be sufficient... Population-based immunity (so, called "herd health") does not work that way. So what is being weighed is the public health benefits against individual libertarian rights. I understand and appreciate BOTH sides of this argument. I only wish that it could be a "clean" argument, devoid of spurious accusations and assertions.

Merck is, of course, the epitome of "big pharm", so some people seem to assume that the only motivation is money.

I won't argue that Merck isn't seeing the profit potential, but that doesn't automatically mean that the process or the product is flawed.

It's difficult to put a price on human suffering. Some AIDS/HIV drugs have historically been ridiculously expensive and have certainly made some pharmaceutical companies a lot of money. Does that mean that they shouldn't have been developed, tested, or used? Nope.

If HPV is a prerequisite to cervical cancer and Gardasil prevents HPV, then Gardasil is effectively an anti-cancer drug. Semantics aside, of course.

Edit: typo

NIH says "HPV is the major cause of cervical cancer." But they also say of the 100 types of HPV, fewer than 20 are considered high risk for cervical cancer.

Lastly, they say the "vast majority" of HPV infections go away without treatment and NO NOT CAUSE CERVICAL CANCER.

Re-read my updated OP.

HPV infection. I answered. So, now you assert that was NOT the question?

When you box yourself in, don't admit your error, just change the question/assertion....:rofl:

HPV causes cervical cancer.

Gardasil prevents HPV.

What part of that do you not understand?

As far as your "updated" OP, I'm not sure that even you know what your point is anymore. If you're saying that we shouldn't use Gardasil because it prevents both cancer-causing HPV and non-cancer-causing HPV, I'd have to disagree.

But then, you're apparently the expert at "good" and "bad" HPV. What's the benefit to keeping the "good" HPV strains along with the "bad"?

Sometimes things aren't as cut and dry as they seem. In the medical establishment absolute certainties aren't always the case. For example, doctors will even tell you that each person's cancer is slightly different then the next, and may require different treatment, etc.

Anyway we all learn from each other, hell I even conceded a point in my OP. :)

for the daughters, nieces, women of the world.

HPV infection is associated with 99.7% of all cervical cancer. SO, because some HPV infections do not go on to result in cancer-- instead of preventing primary infection with HPV via vaccine-- you would opt for women to bet on the chance that the infection will not progress?


Is this REALLY what you want to argue?

From the quote in my OP:

while HPV infections are very common, cervical cancer is not. The vast majority of HPV infections go away without treatment and do not cause cervical cancer.
:shrug:

and women of this country, rather than offer primary protection against a deadly threat. As a male (at least from your profile), do you not feel just a wee bit disingenuous arguing for that?

I'm just presenting another point of view...take a step back and examine ALL the facts surrounding this issue. That's what I'm saying.

Weigh the evidence. Read the full article from NIH I posted in my OP. Then make a decision based on ALL the facts.

It just seems so many here have jumped to conclusions and are basing their pro-Gardasil stance on pure emotion.

a part of the "vast majority"? Having been through a colposcopy and cryotherpy back in the mid-80's for the presence of stage IV pre-cancerous cervical cells, also known as dysplasia, let me tell you that no woman would want to go through this if there is a chance it could be prevented. The virus itself and/or the treatment, also caused my infertility. Had I not had regular gynocological visits, it might not have been caught in time. At the age of 22, I asked what could have caused my problem. The response was, probably a virus of some sort. They knew even back then.

So, what do you suggest? Keeping my legs closed, perhaps? Problem is, that doesn't always work. I got an HPV from my first husband and, trust me, that is the ONLY place I could have gotten it. Would you want something like this to happen to your daughter? Women can be chaste, but if the men haven't been, the chance is always there. Sucks, doesn't it? I hope that they can eventually come up with a vaccination for boys, as well, so that their early promiscuity doesn't affect the health of their future partners.

ETA: My guess is that, if this virus could potentially lead to a man's dick shriveling up, we wouldn't be having this discussion.

I'm just quoting from the National Institutes of Health, and that's what they came up with.

Many people here think that people raising questions about Gardasil are anti-vaccine. But you know what? I would vaccinate my daughters (if I had daughters) for sure. But I would sincerely hope that vaccination would be opt-in rather than mandatory through an anti-democratic executive order. And it's for that reason that I would still raise questions about this if it were men who were affected rather than women.

but, that didn't appear to be the crux of your initial post.

And, I also wanted to clarify, that when I made the comment about men and their appendages, I wasn't specifically referring you or to the discussion we are having here on DU. I was referring to all the bureaucrats at the FDA and others along the way who have done their best to try and prevent this vaccine from being approved to begin with. THAT has nothing to do with opt-in/opt-out policies.

;-D

are associated with cervical cancer among a small minority of women who contract these HPV strains, typically many, many years after they are first exposed to these strains.

You have NO credibilty. None.

Any opinions you express on this subject should logically
be dismissed out-of-hand.

Your persistent habit of 'pretending to miss the point'
doesn't improve your credibility either.

it was sexually transmitted, LOL.

No credibility.

LORDY!

OMG

Not infectious because it's an STD..........O-M-F-G

http://www.democraticunderground.com/discuss/duboard.php?az=show_topic&forum=389&topic_id=145926#146605

http://www.democraticunderground.com/discuss/duboard.php?az=show_topic&forum=389&topic_id=192377#192890

The links bring you to the relevant posts in these monster threads, wait for it.

Do these three nuts get paid by Merck's competitors, perhaps, to slander Gardasil morning, noon, and night??????

They seem to be working together.

So a Med school professor says STDs aren't infectious? Oooookay. Wow. Missed the sockpuppet TS'd disruptor though.

Almost.

Shall we add hypocrisy to the list of things you have demonstrated on these threads?

strains and the risk of deadly cancer, exactly WHY?

When your goose is gored and YOU feel at risk, I'm guessing you'll not be questioning whether YOU deserve the chance to protect yourself.

You go girl. That ought give some of our sock puppet friends something to chew on!! I was trying to stay away today (some fatigue). Still hope a can get some good info on adjuvents at least since I see that nonsense was yet again brought forth.:yourock:

But someone already posted that and did nothing to quiet the storm among the few.. I'm guessing no matter of facts, data, published studies will do so.. "Faith Based Medicine" I guess (and that is no slam against any religion...

Welcome back to the unending anti-vaccine wars...turtlesue

someone sent me a thread about some goings on in the biotech industry. One of my former employers just got sold by the giant company that bought them out a few years ago to some sort of investment company that I believe is going to break them up into pieces putting 700 jobs in jeopardy. They do vaccine work btw which is why I bring this up. The parent company more or less said that my old companie's lack of profits were dragging them down so they jettisoned them. I was listening to alot of very very very upset bloggers who hate the parent company intensely. I will not name them but they are far far worse on money grubbing than Merck. So we can see that vaccine work is soooo profitable that many researchers in the field have their jobs in jeopardy!!!:grr:

most vaccine manufacturing has gone overseas and thus the season flu vaccine shortages we've had in years past... A real pity, too as some who scream against vaccines today will surely wake up to be among the masses crying for them in the future...

It is a vaccine (that's another term for a biological). It stimulates immunity. It is NOT a pharmaceutical (aka drug)!!!!!!!!!! When someone blatantly misuses these terms it is prima facia evidence of their ignorance and automatically disqualifies them from writing about the subject, IMHO.

God, I hate when ignorant people write about things they know nothing about.

Edit to add:
The ability to point and click and cut and paste ALSO does not qualify one to write about a subject. It really is true that a little bit of knowlege is a very dangerous thing. Especially in the hands of pompous folks with hermetically sealed minds.

Edit to add more:
The Gardasil vaccine is as revolutionary and as wonderful a thing as the Feline Leukemia Virus vaccine has been for over 20 years. Prior to its development, it was a normal part of everyday practice to diagnose, "treat" (without success), and euthanize or watch die cats who had been infected, sometimes YEARS before, with FeLV. Eventually the virus did its dirty work and caused either a blod dyscrasia or some sort of CANCER that we could not cure.

Thanks to this vaccine, I RARELY see FeLV cats anymore. The nature of feline practice has completely changed, for the better. One BAD DISEASE is a thing of the dim past for most vets. But I remember. How the hell could I ever forget? And how the hell could I, or any educated person, fail to see how HPV is just another of these nasty killers that we have a chance to banish?

SHAME on the people who don't want this vaccine available FOR ANYONE (because that's what this is really about, folks). SHAME!!!!!

that and about a thousand other aspects of their argument...

:silly:

Sorry, I had other things going on yesterday!

most of the Gardasil conflict.

There really ought to be some rules:
If you don't understand the difference between a drug and a vaccine you can't post about either.
If you don't understand the difference between treatment and prevention you can't post about either.

need to understand the difference between drug, vaccine and CHEMICAL.
I swear to god some people think vaccines are Mercury injections or some such.

Vaccines adjuvants are not biological. They are very pharmacologically active substances.

A recent study has shown that alum injections cause neural death in mice:

http://www.straight.com/article/vaccines-show-sinister-side
http://tinyurl.com/3xhtdz

Vaccines are CLASSIFIED as biologicals, not pharmaceuticals.

Here, I did some of your homework for you:

http://www.google.com/search?q=biologicals+vaccines&rls=com.microsoft:en-us&ie=UTF-8&oe=UTF-8&startIndex=&startPage=1

http://www.gsk-bio.com/webapp/index.jsp

http://www.who.int/biologicals/en/

http://www.google.com/search?q=pharmaceuticals&rls=com.microsoft:en-us&ie=UTF-8&oe=UTF-8&startIndex=&startPage=1

I'm done. Do the reading yourself.

And I'll remind you never to try to tell someone with a BS in Microbiology and a DVM, both from a top American university, what's what with vaccines. I have learned and forgotten more than you could ever begin to comprehend.

That and a real Democrat will get you one person who is not a cheerleader for Bush.

for Bush? Thats just plain wrong and you know it.:grr:

known only to you, is a vaccine but not a biological????????????????????????????????????????

:crazy: :crazy: :crazy: :crazy: :crazy: :crazy: :crazy: :crazy: :crazy:

Ok. Care to explain THAT logic?

(crickets chirping..........)

See? We all learn something out of these debates. :)

I am not anti-vaccine. I would actually vaccinate my daughters if I had any. I'm just bringing some new information into this debate that I hope will be considered.

I am, however, totally against the way this has come about in Texas. Rick Perry's executive order was made with no debate, no votes, and no voice of the people - anti-democratic. Furthermore Perry fast-tracked it's implementation.

More has come out on this board today regarding Merck's huge losses due to billion dollar settlements both here and in Canada. Factor this in with Perry's CLOSE TIES with Merck and that Merck is one of Perry's largest campaign donors and...well...I don't have to tell you.

I think Perry has his mind set on saving Merck, not the children of Texas.

against their parents' wishes to receive this vaccine.

I'm not being snarky (for once). I am quite serious. If it's in there, show me.

No votes, no debate, no will of the people.

Mandatory means you HAVE TO get it. If you don't want to for religious or philosophical reasons, you must request an affadavit, fill it out for each child, have it notarized, then send it back to the State for approval. This is called "opting out."

I may be wrong on this, BUT - I think there are some schools that will not permit students who have not been vaccinated. Again I may be wrong but I believe I came across some info along those lines yesterday.

The argument is: why do people have to opt-out when it should be opt-in.

who has not received an STD vaccine. We're not talking about the common cold here.

Opting out is fine with me. NO ONE is being forced to receive the vaccine.

argument are actually accomplishing something!! I think that you make many good points about Perry and Merck ties and motivations. But there is soo much crap flying around that the REAL issues are lost. There is alot of misinformation being spread around and many of us feel like its our responsibility to put a stop to that, despite the fact that I am not the only one getting a headache from going round and round on this. Staying strictly on your point is fine. But certain people seem to have an agenda here and clouding the issue. Seriously it makes it worth it to me, after the last few days of this, to say that you have learned something!:loveya:

This daily stuff is wearying isn't it. And as a cat lover I really apreciate that particular vaccine too!!:)

And makes me even more anxious to leave this country when I get the chance. This isn't an issue in other countries- like Australia, Britain and Canada.

The logic is simple:

70% of cervical cancers are caused by the variants of HPV that this vaccine protects against.

By conferring immunity to infection, the vaccine will protect girls and women from 70% of the cervical cancers that women are currently getting. QED.

Posts like this are exactly why we need such laws- to protect our kids from prevantable diseases- and from people who are paranoid and/or confused.

That's the question.

scientific community.

Someone raised the analogy to global warming- which while a bit over broad illustrates the point. There's a long and arduous procedure for researching and approving vaccines, and I trust the scientific results.

Too many Americans don't. I wish it weren't an issue- but it is, and so sometimes we have to have laws in place.

The isn't a new issue btw:

See: JACOBSON v. COM. OF MASSACHUSETTS, 197 U.S. 11 (1905).

Facts of the Case

A Massachusetts law allowed cities to require residents to be vaccinated against smallpox. Cambridge adopted such an ordinance, with some exceptions. Jacobson refused to comply with the requirement and was fined five dollars.

Question

Did the mandatory vaccination law violate Jacobson's Fourteenth Amendment right to liberty?

Conclusion

The Court held that the law was a legitimate exercise of the state's police power to protect the public health and safety of its citizens. Local boards of health determined when mandatory vaccinations were needed, thus making the requirement neither unreasonable nor arbitrarily imposed.

http://www.oyez.org/cases/case/?case=1901-1939/1904/1904_70

Debunk the medical RW BS, switch to concerned citizens group that happens to be a RW front.

Go back to another scare tactic involving a strawman about whether its a cancer vaccine, get nailed on it. Switch to government overbearance.

You have a while to catch up with stickfdog though. He's already onto other vaccines that have problems.

The straw is just a-flyin' today, eh?

The next bit of misinformation on this board regarding Gardasil is that it's a cervical cancer drug. But is this really true?

I give up. Are you reading a crystal ball? Someone is going to say that Gardasil is a cervical cancer drug, and you're just pre-empting?

Do a little search, and see how many times I, just for starters, have said IT IS NOT A DRUG.

"Merck Says It's NOT a Cancer Drug."

Whew, they sure do have some smarties there at Merck. If they announce tomorrow that when you drop something it falls down, I'd recommend that Merck be put in charge of that Big World Government and sort us all out.

What we are being told - or at the least what has been confused - is that by making Gardasil mandatory (in the case of Texas), it will save lives by obliterating cervical cancer itself. That is a misperception.

I'd have to say you're right. That's one big misperception you've got there. At least, that would be one word for it, if one were feeling charitable.

I guess I should be happy that at the very least you're not relying on bogus rw BS.

"What we are being told - or at the least what has been confused - is that by making Gardasil mandatory (in the case of Texas), it will save lives by obliterating cervical cancer itself."

Really? Where has anyone said that?

"That is a misperception."

No its a strawman.

:bounce:

Anyway it's been called a "cervical cancer vaccine" in the news and virtually everywhere else. It's not difficult for people to begin to believe it. But in reality it's an HPV vaccine. That is the difference, and it's not a straw man. Whether you are for or against this issue, this is just plain fact.

I remember when this thing was announced. They cited it as a cancer vaccine. The impression people are left with is that it cures, or otherwise protects against, ALL forms of cervical cancer. That's what I'm getting at here. That's the debate.

After all, it doesn't really treat polio, it affects the virus that causes polio.

:eyes:

The ONLY ones in this debate who have referred to the HPV vaccine as a "cervical cancer" vaccine...are the ones who have been on your side.:eyes:

When he isn't swinging wildly at strawmen, he's moving the goal posts.

Which considering you are claiming you have the truth, it's a bit ironic that you seem to be trying to decieve us.

Your headline read "Merck Says It's NOT a Cancer Drug."

But that IS NOT what Merck said according to your own sourcing. What they said was "GARDASIL may not fully protect everyone and does not prevent all types of cervical cancer.."

Not being a cancer drug and being a drug that only help with some types of cancer causing virii are not the same thing.

And then you go onto say "Edited to concede the fact that NIH cites HPV as "the major cause of cervical cancer," although some cases do exist where HPV is not a factor."

But who claimed that ALL cases of cervical cancer are caused by HPV? And you miss and rather important part..lots of cervical cancer cases are caused by HPV, including the one that Guardisil targets.

Drinking orange juice also wont' make you immune from cancer, but it sill helps. A flue shot wont' keep you safe from all forms of the flu, but that doesnt' mean it's ineffective.

I admit, I am not a doctor. I do not have a PhD in Biology. But I can read and I can recognize when someone's sources are contradicting what they are claiming and when they are making bad arguements.

That you keep making so blatently fallacouse arguements and try to mislead (dare i say LIE?) about what Merck and the NIH actually said makes your arguements weak all by themselves.